Literature DB >> 24721428

CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.

Heyu Zhang1, Xu Nan2, Xuefen Li1, Yan Chen3, Jianyun Zhang3, Lisha Sun1, Wenlin Han2, Tiejun Li4.   

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common types of malignancies in the head and neck region. CKLF-like MARVEL transmembrane domain-containing member 5 (CMTM5) has been recently implicated as a tumor suppressor gene in several cancer types. Herein, we examined the expression and function of CMTM5 in oral squamous cell carcinoma. CMTM5 was down-regulated in oral squamous cell lines and tumor samples from patients with promoter methylation. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored CMTM5 expression. In the OSCC cell lines CAL27 and GNM, the ectopic expression of CMTM5-v1 strongly inhibited cell proliferation and migration and induced apoptosis. In addition, CMTM5-v1 inhibited tumor formation in vivo. Therefore, CMTM5 might act as a putative tumor suppressor gene through promoter methylation in oral squamous cell carcinoma.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CMTM5; Oral squamous cell carcinoma; Promoter methylation; Tumor suppressor

Mesh:

Substances:

Year:  2014        PMID: 24721428     DOI: 10.1016/j.bbrc.2014.03.158

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.

Authors:  Y Xiao; Y Yuan; Y Zhang; J Li; Z Liu; X Zhang; Z Sheng; T Xu; X Wang
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

2.  MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt signaling pathway.

Authors:  Youzhong Ren; Hongguang Zhu; Chunyuan Chi; Fanghong Yang; Xin Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Oncogenic and tumor suppressor genes expression in myeloproliferative neoplasms: The hidden side of a complex pathology.

Authors:  Elham Abedi; Mehran Karimi; Ramin Yaghobi; Hamid Mohammadi; Sezaneh Haghpanah; Mohamad Moghadam; Elahe Bayat; Alireza Rezvani; Mani Ramzi
Journal:  J Clin Lab Anal       Date:  2022-02-17       Impact factor: 2.352

4.  CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.

Authors:  Ting Li; Yingying Cheng; Pingzhang Wang; Wenyan Wang; Fengzhan Hu; Xiaoning Mo; Hongxia Lv; Tao Xu; Wenling Han
Journal:  J Exp Clin Cancer Res       Date:  2015-10-16

5.  CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis.

Authors:  Bing Cai; Yunbei Xiao; Yeping Li; Shaobin Zheng
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

6.  Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

Authors:  Shidong Zhang; Run Tian; Chunhua Bei; Huixia Zhang; Juan Kong; Chuanjun Zheng; Xin Song; Di Li; Hongzhuan Tan; Xiaonian Zhu; Shengkui Tan
Journal:  Onco Targets Ther       Date:  2020-06-17       Impact factor: 4.147

Review 7.  CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value.

Authors:  Jie Wu; Lan Li; Siyi Wu; Bin Xu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

8.  Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.

Authors:  Wanqiong Yuan; Ting Li; Xiaoning Mo; Xiaolin Wang; Baocai Liu; Wenyan Wang; Yu Su; Lan Xu; Wenling Han
Journal:  Oncotarget       Date:  2016-05-17

9.  CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling.

Authors:  Gang Xu; Chengxue Dang
Journal:  Cancer Cell Int       Date:  2017-11-29       Impact factor: 5.722

Review 10.  Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer.

Authors:  Keheng Wu; Xiaoman Li; Huadi Gu; Qiao Yang; Yingying Liu; Liang Wang
Journal:  Int J Biol Sci       Date:  2019-09-07       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.